Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-39P is a non-protein-coding pseudogene in the human genome that resembles the sequence of functional U2 small nuclear RNA genes, which are essential components of the spliceosome responsible for pre-mRNA splicing[3][2]. Unlike the canonical U2 snRNA genes, pseudogenes such as RNU2-39P typically arise from duplication and mutation events and do not produce functional RNA products[3]. U2 snRNA pseudogenes are characterized by truncated or altered sequences and lack the necessary elements for stable expression and integration into spliceosomal complexes[3][2]. The known U2 snRNA family plays a critical role in mRNA splicing and post-transcriptional modifications, but pseudogenes like RNU2-39P do not participate in these cellular processes[3]. There is no evidence indicating RNU2-39P is involved in disease, serves as a drug target, or functions as a biomarker. Annotation confusion can arise due to the large number of U2 pseudogenes and challenges in mapping small RNA sequences, but RNU2-39P itself does not represent a receptor, enzyme, or therapeutic target[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 39, pseudogene (RNU2-39P).